This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Blyth, Inc. (BTH), Align Technology, Inc. (ALGN) And Abiomed, Inc. (ABMD) And Investigation Of Peregrine Pharmaceuticals, Inc. (PPHM)

Stocks in this article: ABMD ALGN BTH PPHM

NEW YORK, Dec. 5, 2012 /PRNewswire/ --

Blyth, Inc. Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of Connecticut on behalf of investors who purchased Blyth, Inc. (NYSE: BTH) stock between March 14, 2012 and November 6, 2012.

For more information, click here: http://zlk.9nl.com/blyth-bth .  You have until January 12, 2013 to request that the Court appoint you as lead plaintiff.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Align Technology, Inc. Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who acquired Align Technology, Inc. (NasdaqGS: ALGN) securities between April 23, 2012 and October 17, 2012.

For more information, click here: http://zlk.9nl.com/align-technology-algn/ . You have until January 28, 2013 to request that the Court appoint you as lead plaintiff.

Abiomed, Inc. Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Abiomed, Inc. (Nasdaq: ABMD) stock between August 5, 2011 and October 31, 2012.

For more information, click here: http://zlk.9nl.com/abiomed-abmd .  

Peregrine Pharmaceuticals, Inc. Levi & Korsinsky is investigating potential claims on behalf of purchasers of Peregrine Pharmaceuticals, Inc. (NasdaqCM: PPHM) securities concerning possible breaches of fiduciary duty in connection with the disclosure of the discovery of major discrepancies in the treatment group of its Bavituxmab Phase II Second-Line Non-Small Cell Lung Cancer Trial.

For more information, click here : http://zlk.9nl.com/peregrine-pharmaceuticals-pphm/ .  

Levi & Korsinsky is a national firm with offices in New York and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:     Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free:  (877) 363-5972 Fax: (212) 363-7171 www.zlk.com 

SOURCE Levi & Korsinsky, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,199.75 +8.38 0.05%
S&P 500 1,996.32 -5.84 -0.29%
NASDAQ 4,623.1750 -14.8190 -0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs